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individuals with hypertension from each family (107 patientsAssociation of the tissue kallikrein gene promoter with ESRD
in total) were used in the analysis, an even stronger associationand hypertension.
was observed for this allele (allele specific P  0.003, locusBackground. Kallikreins have long been implicated in hu-
total P  0.01). This allele was more frequent in the hyperten-man essential hypertension and associated complications. In
sive (non-diabetic) patients (0.20 in probands and 0.19 in allparticular, low urinary kallikrein excretion has been associated
ESRD cases) than in the controls (0.12). No evidence of associ-with hypertension and renal disease in African Americans. In
ation in diabetic ESRD patients was observed (P  0.93).an effort to identify the source of differential kallikrein excretion,
Conclusions. The KLK1 promoter is uniquely polymorphic.we investigated the promoter of KLK1, the tissue kallikrein
The observed genetic association suggests an etiologic effectgene. The KLK1 promoter is uniquely polymorphic with a
of the KLK1 promoter on hypertension and/or hypertensionpoly-G length polymorphism coupled with multiple single base
substitutions. In this report, we genetically evaluated the associ- associated ESRD.
ation of KLK1 gene promoter alleles with end-stage renal
disease (ESRD) in African Americans.
Methods. A total of 15 haplotypes were identified in the
Kallikreins are serine proteases that have been inten-KLK1 promoter region through detailed DNA sequence analy-
sively studied in human essential hypertension and asso-sis. This polymorphic region was then genetically evaluated
for association with ESRD in African Americans with diabetic ciated complications. The tissue kallikreins are encoded
and non-diabetic etiologies of ESRD. by a cluster of genes on chromosome 19. Among these
Results. The complex polymorphic nature of the promoter genes, KLK1 encodes kallikrein 1, the principal kinin-presents challenges to determining the alleles. We have rede-
generating enzyme found in the human kidney that isfined the region as six separate loci: five substitution loci and
also expressed in pancreas and saliva. The KLK1 geneone length locus. The length locus was defined as G repeats
starting at position130 and ending at121 on the gene. Among has been mapped to chromosome 19q13.3 [1, 2]. This
four relevant substitution loci for this study, one at position cluster of genes also encodes prostate-specific kallikrein
131, just outside the G repeats, is an A-to-G substitution.
2 and antigen kallikrein 3 [3, 4]. The plasma kallikreinThe other three variant positions are 129, 128, and 127,
(kallikrein B) is encoded by a gene, KLKB1, on chromo-all G-to-C substitutions within the G repeats. This region was
genotyped in African American subjects with and without some 4q34-35 [5, 6]. Using a genetic approach, we have
ESRD using semiautomated sequencing. Four different G re- studied two kallikrein genes, KLK1 and KLKB1, in Afri-
peat alleles ranging from 11.8% for 12 Gs to 52.3% for 10 Gs can American patients with end-stage renal disease
were observed in 86 control subjects. The C substitution of Gs
(ESRD) and a collection of ethnically matched controlsranges from 2.9% at position 127 to 8.2% at 129. When
[7–9]. Significant allelic association was observed be-affected probands from each of 76 hypertensive ESRD families
were genotyped, an association for the 12 G allele, the longest tween microsatellite polymorphisms within and near the
of the length locus alleles, was detected (allele specific P  KLKB1 locus and ESRD. The focus of the current study
0.004 and locus total P  0.02). When all ESRD affected is whether a similar association exists with the tissue
kallikrein gene and ESRD.
Tissue kallikrein processes low molecular weight ki-Key words: kallikrein, tissue kallikrein, promoter structure, polymor-
phism, end-stage renal disease, African Americans. ninogen to produce the potent vasoactive kinin peptide
[10], which is then cleaved by kininase I or II. IntactReceived for publication July 13, 2001
kinins bind to the bradykinin B2 receptor whereas metab-and in revised form September 18, 2001
Accepted for publication October 4, 2001 olites of kininase I, such as Des-Arg (9)-BK or Des-Arg
(10)-Lys-BK, bind to the bradykinin B1 receptor [11]. 2002 by the International Society of Nephrology
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Binding of kinins to their respective receptors activates the DNA sequences of those new alleles, they were cloned
into pCRII vector (Invitrogen, San Diego, CA, USA)second messengers in target tissues and triggers a wide
spectrum of biological effects, such as vasodilation, vaso- and verified by DNA sequencing. A 179 bp fragment of
the 5 flanking region of the human tissue kallikrein geneconstriction, inhibition or stimulation of cell growth [12, 13].
Renal tissue kallikrein has been examined extensively was amplified by polymerase chain reaction (PCR) using
oligonucleotide primers hKPM6 and hKPM7 [23]. Thirtyfor its potential role in human essential hypertension and
associated complications. The observation that urinary cycles of PCR (94C/1 min, 60C/2 min, 72C/3 min) were
performed in a 25 L reaction mixture, containing 25excretion of kallikrein is significantly reduced in hyper-
tensive patients was recorded as early as 1934 [14]. The ng of genomic DNA, 25 pmol of primers, 2.5 L of 2
mmol/L dNTP, 2.5 L of 10 PCR buffer, and 2.5 U offinding has since been confirmed by many studies show-
ing that an association of reduced urinary kallikrein ex- Taq DNA polymerase. The PCR products were purified
by agarose gel, and then cloned into the pCRII vectorcretion exists in hypertensive humans and animal models
[15, 16]. Epidemiologic studies showed that urinary kalli- at its PCR cloning site. These constructs were confirmed
by DNA sequencing performed in the Medical Univer-krein levels are inversely correlated with blood pressure
in infants, children and parents [17–19]. A study involv- sity of South Carolina as described [23].
ing Utah pedigrees indicates that a dominant allele ex-
Study populationspressed as high urinary kallikrein excretion may be asso-
ciated with a decreased risk of essential hypertension Three study populations were used, all of whom were
of African American ethnicity including 85 control sub-[20]. Similarly, a genetic linkage between kallikrein gene
polymorphisms and blood pressure regulation also has jects, 92 type 2 diabetes ESRD patients, and 76 non-
diabetic ESRD families. The 76 non-diabetic ESRD fami-been reported in hypertensive rats [21, 22]. These find-
ings are consistent with the notion that genetic fac- lies were selected based on an index case with hypertension
and ESRD. These families contained 107 total patientstors causing a decrease in renal kallikrein activity might
contribute to the pathogenesis of hypertension or associ- with hypertension and ESRD, and, in addition, some
families had additional ESRD members with chronicated renal complications. However, there is no genetic
evidence pointing to a direct link between mutations in glomerular disease or unknown etiologies of ESRD. The
85 race-matched controls were healthy unrelated em-kallikrein gene and alteration of blood pressure or renal
complications. ployees at North Carolina Baptist Hospital (Winston-
Salem, NC, USA). The 92 unrelated type 2 diabetesWhile searching for potential mutations in the tissue
kallikrein gene KLK1, we previously identified a poly- patients were recruited as part of our ongoing studies of
the genetics of type 2 diabetes associated nephropathy.morphic region in the promoter [23]. This region is un-
usually polymorphic, containing a poly-guanine length The 76 non-diabetic ESRD families were identified
through probands presenting with hypertension associ-polymorphism coupled with multiple substitution poly-
morphisms that constitute at least ten different haplo- ated ESRD. Recruitment and clinical characteristics of
this family set have been previously described [7].types in the121 to131 nucleotides from the transcrip-
tion initiation site. Functional analysis of several haplotype
Genotyping using semiautomated sequencingalleles of this sequence suggests that different haplotype
alleles lead to different levels of expression of the KLK1 To genotype the polymorphic KLK1 promoter region
the DNA was sequenced from this region in the 284 indi-gene [23]. These results suggested that alleles of the KLK1
promoter contribute significantly to the level of kallikrein viduals comprising control, diabetes-associated ESRD,
and hypertension-associated ESRD populations described1 gene expression, and consequently, may be related to
variable levels of urinary kallikrein excretion associated above. PCR primers were designed from the 5 untrans-
lated promoter region of KLK1 cDNA. We designedwith hypertension and renal complications. In this study
we genetically evaluated whether alleles of the KLK1 two primers KLK1A.F (5-AAGGCCAAGGCTTATA
TTTC), which starts 361 bp 5 to the promoter’s 11 bppromoter are associated with major renal complications:
hypertension and diabetes associated ESRD. polymorphic region, and KLK1A.R (5-GAACCAC
ATGGTGACAGAG), which ends 168 bp 3 to this re-
gion. These two primers amplify a 540 bp PCR product
METHODS
containing the polymorphic region. The PCR was carried
Identification of additional alleles for the KLK1 out in the strip-capped PCR tubes in 96 well plates con-
promoter polymorphisms taining 50 L reaction solution in each well [7]. Cycling
conditions were 30 cycles at 94C/1 min, 55C/2 min,Since the initial report of these polymorphisms [23],
additional alleles have been identified through genotyp- 72C/3 min. Five microliters of the solution were ana-
lyzed by agarose gel electrophoresis to determine whe-ing of individuals in expanded populations of subjects
and different ethnic/racial groups. In order to determine ther the PCR amplification was successful. If the PCR
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Fig. 1. Electropherograms of different KLK1
promoter polymorphisms. The sequence calls
of this region generated by the 377 Sequencer
(ABI, Foster City, CA, USA), that is, a ma-
chine read sequence, are shown above the
each figure with N representing an ambiguous
nucleotide calls by the software. This sequence
is annotated at the top of panels A and D
with the numbered bases corresponding to the
terminology we have used to assign the alleles.
The genotypes of the composite loci are listed
underneath each sequence as read visually.
The substitution loci are noted on the left if
they are heterozygous. The blue-colored C’s
on the right, of the sequence below each panel,
mark the beginning of the invariant 3 flanking
sequence (CAATTGTCC . . .) of the length
locus. The numbers of Gs between the A at
position 131 and the C at position 121
constitute the length locus alleles. The com-
plete listing of an individual’s genotypes at
the composite loci and at the haplotype locus
in each electropherogram is in Table 1.
was successful, the remaining 45L of DNA was purified Genotyping of KLK1 promoter polymorphisms
using GeneClean II kit (Bio 101, Vista, CA, USA). Se- Genotyping of the promoter polymorphisms was car-
quencing was done on an ABI 377 Sequencer. In order to ried out by direct DNA sequencing of PCR amplified
achieve optimum peak height of the electropherograms, copies of the promoter region from individual genomic
cycled DNA samples were diluted two- to threefold be- DNAs. Genotypes of the substitution polymorphisms
were determined based on the presence of one or twofore loading onto the sequencing gel.
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Fig. 1. (Continued)
peaks at a specific nucleotide position. Homozygotes are superimposed nucleotides as shown in Figure 1 C-F, re-
spectively. The Poly-G length polymorphism was some-characterized by single peak of two copies of the same
nucleotide, such as seen at positions 131, 129, 128 times difficult to determine in heterozygous individuals
with different length variants. Sequence was determinedand 127 (Fig. 1 and Table 1). Heterozygotes at these
positions are marked by double peaks from two different by identifying the known 3 downstream invariant se-
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Table 1. Complete list of individual genotypes at the composite loci and at the haplotype locus in each electrogram: Figure 1
Allele or
Panel genotype KLK1.(131)A-G KLK1.(129)G-C KLK1.(128)G-C KLK1.(127)G-C KLK1.(130)(G)N Haplotype
1A Allele 1 A G G G 10 A
Allele 2 A G G G 10 A
Genotype A/A G/G G/G G/G 10/10 A/A
1B Allele 1 A G G G 9 I
Allele 2 A G G G 12 K
Genotype A/A G/G G/G G/G 9/12 I/K
1C Allele 1 A G G G 9 I or Q
Allele 2 G G G G 10 A or C
Genotype A/G G/G G/G G/G 9/10 C/I or A/Q
1D Allele 1 A C G G 10 A or G
Allele 2 A G G G 11 F or H
Genotype A/A C/G G/G G/G 10/11 A/F or G/H
1E Allele 1 A G C G 10 A or B
Allele 2 A G G G 11 H or unknown
Genotype A/A G/G C/G G/G 10/11 B/H or A/unknown
1F Allele 1 A G G C 9 A or E
Allele 2 A G G G 10 I or P
Genotype A/A G/G G/G C/G 9/10 A/P or E/I
quence that starts with a CAATTGTCC. The initial C genotypes for the genotype were present in the haplo-
type (Fig. 1 and Table 1).was first identified and then the nucleotide that followed
at each position from this invariant sequence was marked
Manually genotyping the length polymorphismoff the electropherogram. The number of Gs before the
In some cases the length polymorphism was also deter-starting C of the flanking sequence and up to position
mined using a manual genotyping method. The method130 on the promoter was counted (in the case of C
of manually genotyping these single nucleotide repeatsubstitutions, these are also counted, that is, the total
sequences was the same as used to genotype conven-number of nucleotides). This number served as one allele
tional di-, tri-, or tetranucleotide repeat polymorphisms
of the length polymorphism. If an individual was a homo- and has been previously described [7]. We used the oligo-
zygote, no double peaks were observed in this flanking nucleotide primers hKPM6 and hKPM7 [23] for PCR
sequence and any sequence that followed; thus, it could amplification of the polymorphic promoter sequence.
be concluded that the two alleles were the same as seen The lengths of different haplotype allele are shown in
in Figure 1. If an individual was a heterozygote, then Table 2. The results of manual genotyping were com-
the C of a second copy of the downstream invariant pared with semiautomated genotyping results. If there
flanking sequence was identified in the mixed sequences was inconsistency in the results between the two meth-
of the electropherogram, and the nucleotides that fol- ods, genotyping using semiautomated sequencing was
repeated, and these results were used in the final analysis.lowed the C at each position, after the first allele being
marked off, were compared with the corresponding ex-
Association analysispected nucleotides from the invariant flanking sequence.
The allele association analysis was carried out usingIf they matched, the numbers of Gs before the C was
the Relative Predispositional Effect (RPE) techniquedetermined. This number was the second allele for the
[24] as in our previous studies [8, 25]. The RPE approachlength polymorphism. Figure 1 panels B through F show
starts with the calculation of expected frequencies acrosselectropherograms for DNAs containing 9 and 12 Gs
cases and controls for each pair of subject groups. The(1B), 9 and 10 Gs (1C), 9 and 11 Gs (1D–1E), 9 and 10
resulting chi-square (2) statistic for each allele has a
Gs (1F). single degree of freedom (df). Rather than recalculating
After the two sequences of the polymorphic region the expectations after each evaluation of significance,
were determined for an individual, they were compared only the initially significant allele was “removed” from
with the known haplotype alleles, and then haplotype the table and the chi-square tests recalculated. A signifi-
genotypes were determined. If an individual was hetero- cant difference between cases and controls was defined
zygous for one or more of the substitution polymor- as P  0.05.
phisms and the length polymorphism at the same time,
RESULTSthe linkage phase was not known. Then, the allele types
Defining the KLK1 promoter polymorphismsand genotype of the individual could not be uniquely
determined. In that case, possibilities of more than one Song, Chao and Chao initially described 10 sequence
variants (alleles) in the KLK1 promoter region [23]. Inallele type for a particular allele and more than one
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Table 2. The haplotype alleles of human KLK1 promoter polymorphisms
Length of
Allele Sequence (141 to 111 of KLK1 gene)a PCR productb
A TGGGGATCGGAGGGGGGGGGGCAATTGTCCA 179
B TGGGGATCGGAGGCGGGGGGGCAATTGTCCA 179
C TGGGGATCGGGGGGGGGGGGGCAATTGTCCA 179
D TGGGGATCGGGGCGGGGGGGGCAATTGTCCA 179
E TGGGGATCGGAGGGCGGGGGGCAATTGTCCA 179
F TGGGGATCGGAGCGGGGGGGGGCAATTGTCCA 180
G TGGGGATCGGAGCGGGGGGGGCAATTGTCCA 179
H TGGGGATCGGAGGGGGGGGGGGCAATTGTCCA 180
I TGGGGATCGGAGGGGGGGGGCAATTGTCCA 178
J TGGGGATCGGAGGGGGGGGCAATTGTCCA 177
K TGGGGATCGGAGGGGGGGGGGGGCAATTGTCCA 181
M TGGGGATCGGAGGGGGGGGGGGGGCAATTGTCCA 182
P TGGGGATCGGAGGGCGGGGGCAATTGTCCA 178
Q TGGGGATCGGGGGGGGGGGGCAATTGTCCA 178
R TGGGGATCGGAGGGGGGGGGCGGCAATTGTCCA 181
a Underlined and bold font indicates the region containing variant sites
b Primers used in amplification were hKPM6 and hKPM7 (Song et al, 1997)
essence, these alleles are combinations or haplotypes of could be used to explain the R allele at the haplotype
locus. This locus, KLK1.(121)G-C, does not exist inthe individual single nucleotide polymorphisms in com-
bination with a length polymorphism. A total of 15 hap- the alleles with G repeats fewer than 9, such as alleles
J, I, P and Q; that is, the existence of KLK1.(121)G-Clotype alleles have now been identified, including the
newly identified G, J, M, Q, and R haplotypes (Table 2). is conditional on the length locus KLK1.(130)(G)N.
The positions of these composite loci from the start co-Cloning and DNA sequencing confirmed these haplo-
type alleles. don and on the cDNA are given in Table 3. The relation-
ships between alleles of these composite loci and theInitially, we attempted to define each DNA sequence
as a distinct allele of the promoter sequence. However, haplotype locus (summarized in Table 2) are also shown.
if there is more than one polymorphic single nucleotide
Evaluation of the KLK1 promoter polymorphisms insite in this region, or there is length variation at the same
ESRD patients and controlstime, genotypes of individuals for these polymorphisms
could not be determined with certainty. This conse- We genotyped the KLK1 polymorphisms in two
ESRD-based sample collections and one control popula-quently reduced the value of these polymorphisms in
linkage and association analyses. In order for these poly- tion. The C allele of KLK1.(121)G-C, same as the
haplotype R allele (Table 3), was identified in othermorphisms to be useful in linkage and association analy-
ses, we redefined the region as six separate loci: five DNA samples, but was not observed in the African
American populations evaluated in this study. Thus,substitution loci and one length locus as summarized
in Table 3. We call them “composite loci” versus the KLK1.(121)G-C was not polymorphic. All other com-
posite loci were polymorphic in these populations. Duehaplotype locus for the 15 haplotype alleles that were
identified above. to low peak height at the third nucleotide of any single
nucleotide repeat sequences (as shown at position 131The length locus, designated as KLK1.(130)(G)N,
was defined as guanine repeats starting at position 130 in Fig. 1C and Table 1) the KLK1.(131)A-G locus
could not be determined reliably. Only the homozygousand ending at 121 from the transcriptional initiation
site of KLK1. This is the most highly polymorphic of G allele at this position could be determined.
We found that 11 alleles were present at least once inthese loci, with 6 different length alleles ranging from 8
to 13 of the G repeats (Table 3). However, only four a homozygous state. Allele P was only present in the I/P
state (that is, it could be either I or P). Therefore, welength alleles with 9 to 12 of the G repeats were present
in the African American population evaluated in this could not determine whether it was present. Alleles J,
M and R were not found in the African American popu-study. Among the five substitution loci, one at position
131, KLK1.(131)A-G, just outside and adjacent to the lations that we surveyed. The possible alternative allele
type of some alleles could not be explained as any ofregion that defines the length locus, is an A-to-G substitu-
tion. Four others, KLK1.(129)G-C, KLK1.(128)G-C, the 15 haplotype alleles. Allele 2 of the DNA sample in
Figure 1E is labeled as the unknown allele type inand KLK1.(127)G-C are G-to-C substitutions within
the guanine repeat region at positions129,128,127. Table 1. Therefore, there could be new haplotype alleles
in these populations.An additional substitution locus of a G-to-C substitution
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Table 4. Allele frequencies of human KLK1 promoter polymorphisms
NCBH controls Diabetic ESRD patients Hypertensive ESRD probands All hypertensive ESRD patients
Locus (N85) (N92) (N76) (N107)
KLK1.(131)A-G A 0.81 0.90 0.84 0.83
G 0.19 0.10 0.16 0.17
KLK1.(129)G-C G 0.92 0.92 0.92 0.91
C 0.08 0.08 0.08 0.09
KLK1.(128)G-C G 0.94 0.96 0.96 0.95
C 0.06 0.04 0.04 0.05
KLK1.(127)G-C G 0.97 0.96 0.97 0.97
C 0.03 0.04 0.03 0.03
KLK1.(130)(G)N 9 0.22 0.22 0.18 0.17
10 0.52 0.53 0.51 0.50
11 0.14 0.14 0.12 0.14
12 0.12 0.10 0.20 0.19
Since the AG genotype could not be determined, the allele frequencies of KLK1.(131)A-G was calculated from the number of the GG genotype. The frequency
of the G and A alleles were sqrt (GG/N) and 1  sqrt (GG/N), respectively, where sqrt is the square root, GG is the number of the GG genotype, and N is the
total number of individuals.
Table 3. Human KLK1 promoter polymorphisms interpreted as substitution and length variations
Haplotype allele namesb
Position from Position on
Locus namea start codon cDNA A B C D E F G H I J K M P Q R
KLK1.(131)A-G 169 634 A A G G A A A A A A A A A G A
KLK1.(129)G-C 167 636 G G G C G C C G G G G G G G G
KLK1.(128)G-C 166 637 G C G G G G G G G G G G G G G
KLK1.(127)G-C 165 638 G G G G C G G G G G G G C G G
KLK1.(121)G-C 159 644 G G G G G G G G — — G G — — C
KLK1.(130)(G)N 168 635 10 10 10 10 10 11 10 11 9 8 12 13 9 9 12
a Locus name was given based on the nucleotide change and the position of the change in reference to the transcriptional initiation site (Lin et al, 1993). For
example, KLK1(131)A-G means that the locus is an A-to-G substitution at position 131. Likewise, KLK1.(130)(G)N means that it is a repetition of guanines
at position 130, but this includes possible C substitutions in the sequence 121 to 130, that is, the total number of nucleotides.
b Bold type indicates the allelic differences at composite loci from the A allele for the haplotype locus
Association analysis of the KLK1 promoter cant association was observed for four loci (Table 5).
polymorphisms with ESRD Although the G allele frequency at the fifth locus,
KLK1.(131)A-G, was significantly different betweenOur initial attempts to evaluate ESRD association
the controls and the ESRD cases (P value of 0.03; Ta-with haplotypes of the KLK1 promoter were limited
ble 5), the results were based on only a few GG genotypesby the complexity of the sequences. Haplotype analysis
as the AG genotype at this locus could not be deter-using the 15 alleles of the promoter polymorphisms has
mined. In the stratified analysis of the four substitutionlimited power due to many resulting alleles with small
loci, when the diabetic ESRD population (92 cases) wasnumbers of individuals. Instead, we used the composite
analyzed for associations using the allele frequencies cal-loci in our data analysis. There are six composite loci as
culated from 86 control subjects, the allele frequenciesdefined in Table 3. KLK1.(121)G-C is not polymorphic
were similar in the controls and the cases (Table 4). Noin the studied populations. The other five are all poly-
significant allele association was observed (Table 5).morphic in our African American samples. KLK1.(130)
(G)N is a length locus with a varying number of G re-
Association between KLK.(130)(G)N andpeats. KLK1.(131)A-G is an A-to-G substitution out-
hypertension associated ESRDside but next to the G repeat region. KLK1.(129)G-C,
When the probands from each of 76 non-diabetic fami-KLK1.(128)G-C, and KLK1.(127)G-C are all G-to-C
lies were analyzed for association with KLK.(130)substitutions within the G repeat region. The allele fre-
(G)N locus, the 12 G allele of the length locus was ob-quencies of these loci are given in Table 4. The allele
served to be associated with ESRD. The frequencies ofassociation analysis was carried out using the Relative
this allele were 0.12 in the controls, and 0.20 in the hy-Predispositional Effect (RPE) technique as in our pre-
pertensive probands (Table 4). The 12 G allele-specificvious studies [8] and the results are summarized in
P and total P values were 0.004 and 0.02, respectively.Table 5.
The results of evaluating the entire locus (for example,When both diabetic and hypertensive ESRD cases
were analyzed together against the controls, no signifi- using all alleles) were also significant (P  0.05 level; Ta-
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Table 5. Association analysis of human KLK1 promotor polymorphisms with ESRD
Observed Expected Locus
Locus Type of probands N Allele N N Allele P total P
KLK1.(131)A-G Diabetic 184 A 182 176.5 0.68 0.04
ESRD patients G 2 7.5 0.044
Hypertensive 152 A 148 145.8 0.85 0.36
ESRD probands G 4 6.2 0.37
All hypertensive 214 A 208 205.2 0.85 0.34
ESRD patients G 6 8.8 0.35
KLK1.(129)G-C Diabetic 184 G 169 168.9 0.99 0.98
ESRD patients C 15 15.1 0.98
Hypertensive 152 G 140 139.5 0.97 0.89
ESRD probands C 12 12.5 0.9
All hypertensive 214 G 195 196.5 0.92 0.72
ESRD patients C 19 17.6 0.73
KLK1.(128)G-C Diabetic 184 G 176 173.1 0.83 0.37
ESRD patients C 8 10.9 0.39
Hypertensive 214 G 146 143.0 0.8 0.31
ESRD probands C 6 9.0 0.32
All hypertensive 214 G 203 201.4 0.91 0.64
ESRD patients C 11 12.6 0.65
KLK1.(127)G-C Diabetic 184 G 176 178.7 0.84 0.24
ESRD patients C 8 5.3 0.25
Hypertensive 152 G 147 147.6 0.96 0.78
ESRD probands C 5 4.4 0.78
All hypertensive 214 G 207 207.8 0.96 0.75
ESRD patients C 7 6.2 0.75
KLK1.(130)(G)N Diabetic 184 9 41 41.2 0.97 0.94
ESRD patients 10 98 96.2 0.86
11 26 24.8 0.82
12 19 21.7 0.56
Hypertensive 152 9 27 34.1 0.23 0.019
ESRD probands 10 77 79.5 0.78
11 18 20.5 0.58
12 30 17.9 0.004
All hypertensive 214 9 37 47.9 0.11 0.010
ESRD patients 10 107 111.9 0.64
11 30 28.9 0.84
12 40 25.3 0.003
N is the number of alleles. Because the AG genotype of KLK1.(131)A-G could not be distinguished from the AA genotype, the number of G alleles was cal-
culated only from the GG genotype.
ble 5). When all hypertension and ESRD affected indi- low molecular weight kininogen with a subsequent im-
pact on the broad spectrum of biological effects of kinin.viduals from each non-diabetic ESRD family (a total of
If this is true, we hypothesized that one or more KLK1107 patients) were used in the analysis, stronger associa-
promoter alleles should be associated with renal diseasetion was observed between this allele and hypertensive
in the form of end-stage renal disease, since renal diseaseESRD [frequency  0.19, allele P  0.003, total P (all
is associated with variable levels of urinary kallikrein.alleles)  0.001]. Although this latter result is biased due
We have previously reported 10 polymorphic allelesto the use of multiple related subjects, the increased sig-
in the promoter of the tissue kallikrein gene and demon-nificance is consistent with increased allele sharing of this
strated that the alleles direct significantly different levelsallele (that is, consistent with linkage and association).
of KLK1 gene transcription and, presumably, different
levels of kallikrein gene expression [23]. Here, we de-
DISCUSSION scribe five additional alleles. These multiple overlapping
Low levels of urinary kallikrein excretion have con- substitution and length polymorphisms are unusual.
sistently been associated with hypertension and renal Searches of other kallikrein gene sequences have failed
disease [14–19]. Kallikrein excretion has a genetic com- to identify similar promoter sequences in other human
ponent [20] suggesting that specific DNA sequences con- kallikreins or kallikreins from other species. To our
tribute, at least in part, to variation in kallikrein excretion knowledge, this type of polymorphism has not been re-
levels. We hypothesized that if the amount of kallikrein ported in other promoters or genes.
1 synthesis is altered by KLK1 gene promoter polymor- Due to complexity of this polymorphic region, novel
approaches were necessary to determine the DNA se-phisms, this will alter the ability to generate kinin from
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quences in samples that are relatively complex heterozy- els. For example, long-term infusion of purified tissue kal-
likrein attenuated glomerular sclerotic lesions and tubulargotes. Although the haplotype analysis of locus polymor-
phisms is potentially more informative, such analysis is injury via the B2 receptor in hypertensive Dahl salt-sensi-
tive (Dahl-SS) rats without causing an apparent bloodnot feasible for families without the genotype informa-
tion for parents, since the linkage phase between differ- pressure reduction [26, 27]. We also demonstrated that
somatic delivery of the tissue kallikrein gene induces aent loci is unknown in the siblings. Our treatment of
these polymorphisms as composite loci enabled us to prolonged blood pressure reduction, attenuates renal in-
juries, and improves renal function in hypertensive andbreak the complex polymorphisms into simple substitu-
tion and length polymorphisms, and to use them in asso- chronic renal failure in animal models [28–32]. In Dahl-SS
rats fed a high salt diet, kallikrein gene delivery not onlyciation analyses.
In this study, these polymorphisms were genotyped offers protection, but also reverses renal injuries including
glomerular sclerotic lesions, basement membrane thick-using semiautomated sequencing. As more and more
genome sequence information is available through the ening, tubular dilation and extracellular matrix accumu-
lation [30]. These findings collectively suggest that tissueHuman Genome Project, direct sequencing becomes a
viable alternative to the traditional STS-based genotyp- kallikrein may have a direct role in hypertensive ESRD.
It has been shown that deleting the region at 144/ing. However, direct sequencing on currently available
instruments presents many problems. It is sometimes 98 caused a dramatic reduction in promoter activity of
the tissue kallikrein gene, suggesting the importance of thedifficult to determine the nucleotide composition by ex-
amining the signal peaks at a specific nucleotide position 144/98 region in transcriptional regulation [23]. The
144/98 region encompasses the promoter polymorph-in a mixed genomic sequence. This is especially true in
the case of our study when complex polymorphisms are isms in this report. It is possible that the multiple alleles
at this polymorphic locus play a role in regulating tissueinvolved. To overcome this limitation, we first identified
the beginning nucleotide of the invariant flanking se- kallikrein promoter activity, leading to change in the
expression of the gene in tissues. Of particular interestquence that is downstream to the polymorphic region,
and then manually read the sequence against the ex- is the notion that allele length may be involved in the
regulatory mechanism. A preliminary study has indeedpected sequence (Fig. 1 and Table 1). In this way, we
were able to eliminate background peaks and identify showed that the B allele is associated with high renal
kallikrein expression while the K allele is associated withthe two alleles of the heterozygotes.
Finally, in the genetic analysis of different alleles in the low renal kallikrein expression (L. Chao, unpublished ob-
servations). Our study showed that the 12 G allele ofKLK1 promoter we observed allelic association between
allele 12 G of the KLK1.(130)(G)N locus and ESRD KLK1.(130)(G)N corresponding exactly to haplotype
allele K is associated with hypertensive ESRD. There isin a population of hypertensive ESRD cases when a
comparable population was used as controls. Interest- a significant excess of this allele in the hypertensive cases.
Higher frequency of the K allele and lower kallikreiningly, no association for this allele was observed in dia-
betic ESRD cases, suggesting the association in hyper- seem to explain hypertensive ESRD. The precise mecha-
nism by which the tissue kallikrein gene plays a role intension-associated ESRD patients was due to the allelic
association between the KLK1 promoter polymorphisms hypertensive ESRD remains to be elucidated.
The results of our study suggest that the 12 G promoterand hypertensive ESRD in these patients.
Assuming genetic variation in the KLK1 promoter allele of KLK1.(130)(G)N, present in 10 to 20% of
African Americans studied here, is a risk factor for devel-leads to change in tissue kallikrein levels, one possible
reason for the observed association between the KLK1 opment of ESRD in the presence of hypertension, but
not diabetes. Based on this data the 12 G promoter al-promoter polymorphisms and hypertensive ESRD may
be explained by the suspected role played by tissue kalli- lele has a risk ratio  1.67 (95% CL  0.9719 to 2.8582).
KLK1 is, however, only one of many kallikrein geneskrein in essential hypertension. In turn, hypertension is
an important contributing factor to the development of that have now been identified. The overall relative con-
tribution of KLK1 to ESRD risk cannot be determinedESRD. Alternatively, reduced renal tissue kallikrein may
have a direct impact on the development of hypertensive from this study alone. In separate studies we have also
implicated the plasma kallikrein gene, KLKB1, as a con-ESRD. An important aspect of the tissue kallikrein-kinin
system is its location in the kidney, that is, the renal tributor for ESRD risk though the mechanism by which
this risk is contributed is unclear [8, 9]. These resultsdistal tubules and connecting ducts. The involvement of
the renal tissue kallikrein-kinin system in renal sodium pose a variety of additional questions including whether
these genetic associations will be seen in other popula-and water excretion suggests that renal kallikrein may
participate both in blood pressure homeostasis and kid- tions such as Caucasians. It is interesting to note that
Placha et al have reported an association between KLK1ney function. The potential role of tissue kallikrein in renal
protection has been investigated in several animal mod- promoter polymorphisms and hypertension, salt sensi-
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